Volume 57, Issue 4

On Estimating Medical Cost and Incremental Cost‐Effectiveness Ratios with Censored Data

Hongwei Zhao

Corresponding Author

Department of Biostatistics, University of Rochester, Rochester, New York 14642, U.S.A.

*email:zhao@bst.rochester.eduSearch for more papers by this author
Lili Tian

Department of Biostatistics, University of Rochester, Rochester, New York 14642, U.S.A.

Search for more papers by this author
First published: 21 May 2004
Citations: 55

Abstract

Summary. Medical cost estimation is very important to health care organizations and health policy makers. We consider cost‐effectiveness analysis for competing treatments in a staggered‐entry, survival‐analysis‐based clinical trial. We propose a method for estimating mean medical cost over patients in such settings. The proposed estimator is shown to be consistent and asymptotically normal, and its asymptotic variance can be obtained. In addition, we propose a method for estimating the incremental cost‐effectiveness ratio and for obtaining a confidence interval for it. Simulation experiments are conducted to evaluate our proposed methods. Finally, we apply our methods to a clinical trial comparing the cost effectiveness of implanted cardiac defibrillators with conventional therapy for individuals at high risk for ventricular arrhythmias.

Number of times cited according to CrossRef: 55

  • Healthcare Utilization and Costs for Patients With Parkinson's Disease After Deep Brain Stimulation, Movement Disorders Clinical Practice, 10.1002/mdc3.12765, 6, 5, (369-378), (2019).
  • ccostr: An R package for estimating mean costs with censored data, Journal of Open Source Software, 10.21105/joss.01593, 4, 41, (1593), (2019).
  • Modeling right-censored medical cost data in regression and the effects of covariates, Statistical Methods & Applications, 10.1007/s10260-018-0428-0, 28, 1, (143-155), (2018).
  • Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non–Small-Cell Lung Cancer After Definitive Radiation Therapy, Clinical Lung Cancer, 10.1016/j.cllc.2018.03.012, 19, 4, (e517-e528), (2018).
  • Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer, Journal of Clinical Oncology, 10.1200/JCO.2017.75.5371, 36, 18, (1823-1830), (2018).
  • Estimation of Mean Health Care Costs and Incremental Cost-effectiveness Ratios with Possibly Censored Data, The Stata Journal: Promoting communications on statistics and Stata, 10.1177/1536867X1501500305, 15, 3, (698-711), (2018).
  • Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders, Statistical Methods in Medical Research, 10.1177/0962280218759137, (096228021875913), (2018).
  • An improved survival estimator for censored medical costs with a kernel approach, Communications in Statistics - Theory and Methods, 10.1080/03610926.2017.1400059, 47, 23, (5702-5716), (2017).
  • Chapter 5: Overview of Statistical Analysis in Biomedical Research, Understanding Health Outcomes and Pharmacoeconomics, 10.21019/9781582122823, (2017).
  • Empirical likelihood‐based confidence intervals for mean medical cost with censored data, Statistics in Medicine, 10.1002/sim.7402, 36, 25, (4061-4070), (2017).
  • Evaluating Utility Measurement From Recurrent Marker Processes in the Presence of Competing Terminal Events, Journal of the American Statistical Association, 10.1080/01621459.2016.1166113, 112, 518, (745-756), (2017).
  • Nonparametric estimation of medical cost quantiles in the presence of competing terminal events, Biostatistics & Epidemiology, 10.1080/24709360.2017.1342185, 1, 1, (78-91), (2017).
  • A doubly robust approach for cost–effectiveness estimation from observational data, Statistical Methods in Medical Research, 10.1177/0962280217693262, (096228021769326), (2017).
  • Semiparametric Estimation of Longitudinal Medical Cost Trajectory, Journal of the American Statistical Association, 10.1080/01621459.2017.1361329, (0-0), (2017).
  • Estimating the cumulative mean function for history process with time‐dependent covariates and censoring mechanism, Statistics in Medicine, 10.1002/sim.6998, 35, 25, (4624-4636), (2016).
  • Model-Based Methodology for Analyzing Incomplete Quality-of-Life Data and Integrating Them into the Q-Twist Framework, Medical Decision Making, 10.1177/0272989X02239650, 23, 1, (54-66), (2016).
  • Using inverse-weighting in cost-effectiveness analysis with censored data, Statistical Methods in Medical Research, 10.1191/0962280202sm308ra, 11, 6, (539-551), (2016).
  • Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies, Statistical Methods in Medical Research, 10.1191/0962280202sm305ra, 11, 6, (469-490), (2016).
  • Median-based incremental cost-effectiveness ratios with censored data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2015.1052482, 26, 3, (552-564), (2015).
  • Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios, Statistics in Medicine, 10.1002/sim.6594, 34, 30, (4057-4069), (2015).
  • Quantile regression methods with varying-coefficient models for censored data, Computational Statistics & Data Analysis, 10.1016/j.csda.2015.02.011, 88, (154-172), (2015).
  • Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12, JNCI: Journal of the National Cancer Institute, 10.1093/jnci/djv106, 107, 7, (2015).
  • Cost-Effectiveness Analysis: A Proposal of New Reporting Standards in Statistical Analysis, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2013.860157, 24, 2, (443-460), (2014).
  • Statistical analysis of cost–effectiveness data from randomized clinical trials, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1586/14737167.6.3.337, 6, 3, (337-346), (2014).
  • Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data, Journal of Statistical Theory and Practice, 10.1080/15598608.2013.771556, 7, 2, (304-323), (2013).
  • Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs, Biostatistics, 10.1093/biostatistics/kxt002, 14, 3, (422-432), (2013).
  • Cost‐Effectiveness of Cardiac Resynchronization Therapy in the MADIT‐CRT Trial, Journal of Cardiovascular Electrophysiology, 10.1111/j.1540-8167.2012.02413.x, 24, 1, (66-74), (2012).
  • Nonparametric Inference for Median Costs with Censored Data, Biometrics, 10.1111/j.1541-0420.2012.01755.x, 68, 3, (717-725), (2012).
  • Median-Based Incremental Cost-Effectiveness Ratio (ICER), Journal of Statistical Theory and Practice, 10.1080/15598608.2012.695571, 6, 3, (428-442), (2012).
  • Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare, Value in Health, 10.1016/j.jval.2012.03.1388, 15, 5, (656-663), (2012).
  • Average Cost-Effectiveness Ratio with Censored Data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2010.544437, 22, 2, (401-415), (2012).
  • Some insight on censored cost estimators, Statistics in Medicine, 10.1002/sim.4295, 30, 19, (2381-2388), (2011).
  • Estimating the mean of a mark variable under right censoring on the basis of a state function, Computational Statistics & Data Analysis, 10.1016/j.csda.2010.10.028, 55, 4, (1726-1735), (2011).
  • Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti, PLoS Medicine, 10.1371/journal.pmed.1001095, 8, 9, (e1001095), (2011).
  • Estimation of life‐years gained and cost effectiveness based on cause‐specific mortality, Health Economics, 10.1002/hec.1648, 20, 7, (842-852), (2010).
  • Two‐sample nonparametric likelihood inference based on incomplete data with an application to a pneumonia study, Biometrical Journal, 10.1002/bimj.200900131, 52, 3, (348-361), (2010).
  • Analyzing Incomplete Data Subject to a Threshold using Empirical Likelihood Methods: An Application to a Pneumonia Risk Study in an ICU Setting, Biometrics, 10.1111/j.1541-0420.2009.01228.x, 66, 1, (123-130), (2009).
  • Cost Analysis With Censored Data, Medical Care, 10.1097/MLR.0b013e31819bc08a, 47, Supplement, (S115-S119), (2009).
  • Patient Health Status and Costs in Heart Failure, Circulation, 10.1161/CIRCULATIONAHA.108.820472, 119, 3, (398-407), (2009).
  • A Study on Confidence Intervals for Incremental Cost‐Effectiveness Ratios, Biometrical Journal, 10.1002/bimj.200810439, 50, 4, (505-514), (2008).
  • Survival models for cost data: The forgotten additive approach, Statistics in Medicine, 10.1002/sim.3215, 27, 18, (3585-3597), (2008).
  • A two‐part model for censored medical cost data, Statistics in Medicine, 10.1002/sim.2847, 26, 23, (4273-4292), (2007).
  • On the equivalence of some medical cost estimators with censored data, Statistics in Medicine, 10.1002/sim.2882, 26, 24, (4520-4530), (2007).
  • Cost‐effectiveness analysis in colorectal cancer using a semi‐Markov model, Statistics in Medicine, 10.1002/sim.3112, 26, 30, (5557-5571), (2007).
  • Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, 10.1200/JCO.2006.09.4342, 25, 16, (2256-2261), (2007).
  • On estimating treatment effects under non‐compliance in randomized clinical trials: are intent‐to‐treat or instrumental variables analyses perfect solutions?, Statistics in Medicine, 10.1002/sim.2663, 26, 5, (954-964), (2006).
  • The Cost Effectiveness of Implantable Cardioverter-Defibrillators, Journal of the American College of Cardiology, 10.1016/j.jacc.2006.03.032, 47, 11, (2310-2318), (2006).
  • Estimating Incremental Cost‐Effectiveness Ratios and Their Confidence Intervals with Differentially Censored Data, Biometrics, 10.1111/j.1541-0420.2005.00502.x, 62, 2, (570-575), (2006).
  • Medical cost analysis: Application to colorectal cancer data from the SEER Medicare database, Contemporary Clinical Trials, 10.1016/j.cct.2005.05.004, 26, 5, (586-597), (2005).
  • Non‐parametric estimation of mean customer lifetime value, Journal of Interactive Marketing, 10.1002/dir.20049, 19, 4, (48-66), (2005).
  • Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach, Health Economics, 10.1002/hec.915, 14, 5, (457-470), (2004).
  • Regression methods for cost‐effectiveness analysis with censored data, Statistics in Medicine, 10.1002/sim.1794, 24, 1, (131-145), (2004).
  • Bayesian estimation of cost‐effectiveness from censored data, Statistics in Medicine, 10.1002/sim.1740, 23, 8, (1297-1309), (2004).
  • On estimators of medical costs with censored data, Journal of Health Economics, 10.1016/j.jhealeco.2003.06.006, 23, 3, (615-625), (2004).
  • Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp Trial, European Journal of Gastroenterology & Hepatology, 10.1097/00042737-200406000-00006, 16, 6, (543-549), (2004).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.